NEO — NeoGenomics, Inc.
Is NEO overbought or oversold? Here is the current MarketMoodz read.
NeoGenomics, Inc. (NEO) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $15.41. The rating moved from Oversold to Strong Oversold on November 14, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$15.41
- Last changeMoved from Oversold to Strong Oversold on November 14, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
See all oversold Healthcare stocks →
AI analysis
NeoGenomics combines a specialized oncology testing platform with national scale, positioning it to benefit from long-term growth in precision oncology and outsourced lab services. Near-term catalysts include earnings clarity, new test adoption and potential partnership or M&A activity, while headwinds center on reimbursement dynamics, payer audits and competition from larger labs. Given mixed macro sentiment and active regulatory focus on Medicare programs, performance over the next month will likely be driven by company-specific execution on growth, margin control and evidence of durable test volume trends.
Key factors
- Leading oncology-focused diagnostics and lab testing franchise with a broad specialty test menu that supports recurring revenue from cancer diagnostics and monitoring
- Exposure to structural growth in oncology testing, precision medicine and outsourced lab services as biopharma and providers expand specialty testing
- Scale and national lab footprint that enable pricing leverage, faster test turnaround and integration with oncology care pathways
- Sector tailwinds: consolidation/acquisition activity among large pharmas and increased outsourcing to biopharma services and specialty distributors
- Potential M&A optionality and partnerships that can accelerate revenue diversification into higher-margin molecular/NGS services
- Balanced near-term market tone with limited macro shocks, allowing company-specific catalysts (earnings, contract wins, test launches) to drive moves
Risks
- Reimbursement pressure and evolving payer policies (including Medicare Advantage integrity actions) that could reduce realized pricing or trigger recoupments
- Competition from large national labs and emerging specialty diagnostics players that can pressure volumes and margins
- Regulatory and compliance risk tied to billing, coding and payer audits that could impose retroactive adjustments or fines
- Operational integration risk from capacity expansion or inorganic growth that could temporarily weigh margins and cash flow
- Macroeconomic and rate-path uncertainty that can slow provider capital spend, affect elective procedure volumes, or constrain M&A financing
- Limited real-time social sentiment and public news in the immediate window increases uncertainty around short-term momentum
See today's live rating, score and targets
Members see the live hourly rating for NEO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.